AYTU Stock Overview
A pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Aytu BioPharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.51 |
| 52 Week High | US$3.45 |
| 52 Week Low | US$1.41 |
| Beta | -1.4 |
| 11 Month Change | -31.76% |
| 3 Month Change | -38.19% |
| 1 Year Change | -39.91% |
| 33 Year Change | -96.13% |
| 5 Year Change | -99.08% |
| Change since IPO | -100.00% |
Recent News & Updates
Investors Don't See Light At End Of Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Tunnel And Push Stock Down 32%
Nov 15
Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly?
Nov 01Recent updates
Investors Don't See Light At End Of Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Tunnel And Push Stock Down 32%
Nov 15Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly?
Nov 01It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year
Jun 20Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden
Jun 14US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results
Feb 17Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Feb 16Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?
Jan 23Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too
Sep 29Aytu stock falls amid suspending clinical programs to save costs
Oct 13Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95M
Sep 27Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorder
Sep 14Aytu gets US patent for AR101/Enzastaurin for circulatory system disorders
Aug 16Aytu BioPharma plunges on pricing $10M stock and warrants offering
Aug 09Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00
May 19Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?
Sep 11Aytu BioPharma up 21% in afternoon trading
Jun 21Increases to Aytu Biopharma, Inc.'s (NASDAQ:AYTU) CEO Compensation Might Cool off for now
May 15Shareholder Returns
| AYTU | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -2.7% | -3.8% | -1.0% |
| 1Y | -39.9% | 9.8% | 30.3% |
Return vs Industry: AYTU underperformed the US Pharmaceuticals industry which returned 9.8% over the past year.
Return vs Market: AYTU underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| AYTU volatility | |
|---|---|
| AYTU Average Weekly Movement | 9.7% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AYTU has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AYTU's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 102 | Josh Disbrow | aytubio.com |
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency.
Aytu BioPharma, Inc. Fundamentals Summary
| AYTU fundamental statistics | |
|---|---|
| Market cap | US$9.16m |
| Earnings (TTM) | -US$7.28m |
| Revenue (TTM) | US$79.76m |
0.1x
P/S Ratio-1.3x
P/E RatioIs AYTU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AYTU income statement (TTM) | |
|---|---|
| Revenue | US$79.76m |
| Cost of Revenue | US$25.50m |
| Gross Profit | US$54.26m |
| Other Expenses | US$61.54m |
| Earnings | -US$7.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.18 |
| Gross Margin | 68.03% |
| Net Profit Margin | -9.13% |
| Debt/Equity Ratio | 55.5% |
How did AYTU perform over the long term?
See historical performance and comparison